Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice

4 May 2021

Abstract excerpt

Sickle cell anemia (SCA) results from an abnormal sickle hemoglobin (HbS). HbS polymerizes upon deoxygenation, resulting in red blood cell (RBC) sickling and membrane damage that cause vaso-occlusions and hemolysis. Sickle RBCs contain less adenosine triphosphate and more 2,3-diphosphoglycerate than normal RBCs, which allosterically reduces hemoglobin (Hb) oxygen (O2) affinity (ie, increases the partial pressure...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erythrocyte Function and Pathophysiology
Share to Hemoglobinopathies and Related Disorders
Share to Neonatal Health and Biochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33944896
DOI: 10.1182/bloodadvances.2020003604

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA micePMID 33944896Read ↗

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell diseaseSemantic proximity Read ↗

Red blood cell pyruvate kinase properties in Townes and Berkeley sickle cell disease mouse models – Of mice and menSemantic proximity Read ↗

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditionsSemantic proximity Read ↗

Pathophysiological-Based Approaches to Treatment of Sickle Cell DiseaseSemantic proximity Read ↗

Sickle Cell Anemia and Antisickling Agents Then and NowSemantic proximity Read ↗

Pyruvate kinase deficiency modifies sickle hemoglobin carrier and sickle cell disease phenotypes in mice.Semantic proximity Read ↗

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell DiseaseSemantic proximity Read ↗

Phenotypic screening of the ReFrame Drug Repurposing Library to discover new drugs for treating sickle cell diseaseSemantic proximity Read ↗

Novel approach towards pathogenesis and treatment of sickle cell diseaseSemantic proximity Read ↗

Physiological and pharmacological factors affecting sickle cell functionSemantic proximity Read ↗

Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular levelSemantic proximity Read ↗

Targeting sickle cell disease root-cause pathophysiology with small moleculesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.